Denosumab biosimilar (Sandoz)

地舒单抗生物类似药 (Sandoz)

Report date: 2024/08/14 17:35:14

Base Information

Drug NameDenosumab biosimilar (Sandoz)
Drug Alias Name地舒单抗生物仿制药 (Sandoz)denosumab-bbdz德尼单抗生物仿制药 (Sandoz)迪诺舒单抗生物仿制药 (Sandoz)Jubbonti® +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[6] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/03/05
Country/TerritoryCzechiaBulgariaUnited States +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgSandoz
China Registration ClassN/A

Develop Information

Active CompaniesSandozHexal AgSandoz Inc +[4] 
Inactive CompaniesN/A
Active IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeM05BX04
Related LinksN/A